• Jeffrey J Swigris, Kevin K Brown, Juergen Behr, Roland M du Bois, Talmadge E King, Ganesh Raghu, and Frederick S Wamboldt.
• Interstitial Lung Disease Program in the Autoimmune Lung Center and Division of Psychosocial Medicine, National Jewish Health, Denver, CO, USA. swigrisj@njc.org
• Respir Med. 2010 Feb 1;104(2):296-304.

RationaleHealth-related quality of life (HRQL) is an important outcome in drug trials. Little is known about how the Short Form-36 (SF-36) and Saint George's Respiratory Questionnaire (SGRQ) perform in idiopathic pulmonary fibrosis (IPF).ObjectivesTo examine the validity of the SF-36 and SGRQ and to determine scores from each that would constitute a minimum important difference (MID).MethodsWe analyzed data from a recently completed trial that enrolled subjects with well-defined IPF who completed the SF-36, SGRQ, and Baseline/Transition Dyspnea Index at baseline and six months. We compared mean changes in HRQL scores between groups of subjects whose disease severity changed over six months according to clinical anchors (FVC, DLCO, and dyspnea). We estimated the MID for each domain by using both anchor- and distribution-based approaches.Main ResultsResults supported the validity of the SF-36 and SGRQ for use in longitudinal studies. Mean changes in domain scores differed significantly between subjects whose clinical status improved and those whose clinical status declined according to the anchors. MID estimates for the SF-36 ranged from 2-4 points and from 5-8 points for the SGRQ.ConclusionIn IPF, the SF-36 and SGRQ possess reasonable validity for differentiating subjects whose disease severity changes over time. More studies are needed to continue the validation process, to refine estimates of the MIDs for the SF-36 or SGRQ, and to determine if a disease-specific instrument will perform better than either of these.

18 keywords...

hide…